Rivaroxaban, heparin and enoxaparin as thromboprophylaxis agents for gynecology oncologic surgery

Comparison of the efficacy and safety of rivaroxaban and heparin and enoxaparin as thromboprophylaxis agents for gynecology oncologic surgery

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20151020024625N19

Enrollment

Registered

2024-05-29

Start date

2024-05-21

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Venous thromboembolism. Condition 2: Pulmonary embolism. Other venous embolism and thrombosis Pulmonary embolism

Interventions

Intervention 1: Intervention group: In group 1, patients receive rivaroxaban 10 mg once a day for 30 days after surgery and discharge from the hospital. Intervention 2: Intervention group: In group 2,

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Candidates for gynecologic oncologic surgery

Exclusion criteria

Exclusion criteria: Receiving anticoagulants agents at present Contraindication for anticoagulants Uncontrolled cardiovascular and cerebrovascular diseases

Design outcomes

Primary

Measure	Time frame
Presence of venous thromboembolism. Timepoint: Seven, 14 and 30 days after surgery. Method of measurement: Doppler ultrasound.	—

Secondary

Measure	Time frame
Venous thromboembolism related mortality. Timepoint: Up to 30 days after surgery. Method of measurement: Death of the patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Saffarieh

Semnan University of Medical Sciences

eli_saffarieh@yahoo.com+98 23 3346 0055

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026